# A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT07218341** · PHASE4 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 150 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Lymphoma, Small Lymphocytic

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT07218341
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2030-05
- **Final completion:** 2032-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218341, "A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07218341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*